NorPACT-1

NorPACT-1 is a multicentre, randomised, phase 2 trial done in 12 hospitals in Norway, Sweden, Denmark and Finland.

Between February 2017 and April 2021, 140 patients with resectable pancreatic head cancer were randomly assigned to receive neoadjuvant FOLFIRINOX or to undergo upfront surgery. Primary endpoint was overall survival at 18 months.

https://clinicaltrials.gov/study/NCT02919787

NorPACT-2

NorPACT-2 is a prospective, population-based cohort study of consecutive patients with borderline resectable and locally advanced pancreatic cancer within a geographically defined population of 3.1 million in the South-Eastern Regional Health Authority in Norway. All patients received primary chemotherapy and were evaluated at Oslo University Hospital. Between January 2018 and December 2020, 230 patients were included. Primary end points were resection rates and survival.

https://classic.clinicaltrials.gov/ct2/show/study/NCT04423731